Scott Thacher/LinkedIn
Nov 25, 2024, 15:06
Scott Thacher: State cancer agency awards $89 million in grants to Texas institutions and companies
Scott Thacher, CEO and founder of Orphagen Pharmaceuticals, shared a post on LinkedIn:
“Texas calls.
The Cancer Prevention and Research Institute of Texas (CPRIT) announced today that it plans to award Orphagen a $10.2 M product development grant over three years to partially fund the final steps towards IND filing and a Phase 1 clinical trial of OR-449, a novel therapeutic candidate for an intractable cancer, adrenocortical cancer (ACC). OR-449 may be developed subsequently in head and neck and lung squamous cancers as a therapy for the 3-10% of these tumors where its target is highly expressed.”
Read more about Orphagen.
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 25, 2024, 09:00
Dec 25, 2024, 03:51
Dec 25, 2024, 03:32
Dec 25, 2024, 02:57
Dec 25, 2024, 01:50